Our founding partners

• Cambridge Innovation Capital

  Cambridge Innovation Capital backs world-leading life sciences and technology companies with an affiliation to Cambridge, Europe’s leading capital for innovation. Cambridge Innovation Capital is the preferred investor for the University of Cambridge, and has extensive access to investment opportunities in the ecosystem. and beyond

• Genentech

  Genentech is a biotechnology company dedicated to pursuing ground-breaking science to discover and develop medicines for people with serious and life-threatening diseases. Their transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

• Dr Ian Tomlinson

  Ian is a pharma R & D leader, biotech entrepreneur and antibody engineer. Ian was previously the co-founder (alongside Sir Greg Winter) and CSO for Domantis, which was sold in January 2007 to GSK for $454m. Ian has previously been SVP and Head of Worldwide Business Development for GSK and chair of both Stevenage Bioscience Catalyst and Apollo Therapeutics.

• Babraham Research Campus

  Babraham Research Campus Ltd is responsible for the development and management of the Campus on behalf of its shareholders; BBSRC-UKRI and the Babraham Institute. The Campus is one of the UK’s leading places to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute.

• Dr Jonathan Milner and Meltwind Advisory

  Dr Jonathan Milner (founder and former CEO of Abcam) is a serial biotech investor and entrepreneur. Jonathan actively invests as an angel across the life sciences and tech spaces, supporting early-stage companies throughout their journey. Jonathan is assisted in his investment activities by Meltwind Advisory, his due diligence and portfolio management organisation which is run by his adviser, Mike Murphy.

Our partners and collaborators